OPRX vs. RMNI, LLNW, RGP, RDWR, OLO, XMTR, VVI, CNDT, IMXI, and IIIV
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Rimini Street (RMNI), Limelight Networks (LLNW), Resources Connection (RGP), Radware (RDWR), OLO (OLO), Xometry (XMTR), Viad (VVI), Conduent (CNDT), International Money Express (IMXI), and i3 Verticals (IIIV).
Rimini Street (NASDAQ:RMNI) and OptimizeRx (NASDAQ:OPRX) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
In the previous week, OptimizeRx had 1 more articles in the media than Rimini Street. MarketBeat recorded 3 mentions for OptimizeRx and 2 mentions for Rimini Street. Rimini Street's average media sentiment score of 1.70 beat OptimizeRx's score of 0.93 indicating that OptimizeRx is being referred to more favorably in the news media.
Rimini Street received 9 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 63.49% of users gave Rimini Street an outperform vote while only 63.16% of users gave OptimizeRx an outperform vote.
Rimini Street has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Rimini Street presently has a consensus target price of $4.50, indicating a potential upside of 75.10%. OptimizeRx has a consensus target price of $16.00, indicating a potential upside of 32.67%. Given OptimizeRx's higher possible upside, equities research analysts plainly believe Rimini Street is more favorable than OptimizeRx.
73.8% of Rimini Street shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 41.3% of Rimini Street shares are held by company insiders. Comparatively, 4.4% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.
Rimini Street has a net margin of 5.02% compared to Rimini Street's net margin of -23.10%. Rimini Street's return on equity of -6.96% beat OptimizeRx's return on equity.
Summary
Rimini Street beats OptimizeRx on 11 of the 18 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
